Table 1.

Summary of the effects of zotepine (ZTP) on astroglial L-glutamate release and Cx43 expression in the astrocyte.

	Therapeutic-Relevant	Supratherapeutic	Therapeutic-Relevant	Supratherapeutic
Release	Basal	(ACSF)	Activated	(HK-ACSF)
Acute	Non	Increase GAP19(-)	Non	Increase GAP19(+) DEBC(-)	Figure 1, Figure 2 and Figure 3
Subchronic	Non	Increase, GAP19(+) DEBC (-)	Non	Increase GAP19(+) DEBC(+)	Figure 1, Figure 2 and Figure 3
Chronic	Increase		Increase		Figure 8
Cx43 Expression	Cytosol		Plasma membrane
Acute				Non	Figure 7
Subchronic	Non	Increase	Non	Increase DEBC (+)	Figure 4, Figure 5 and Figure 6
Chronic			Increase		Figure 7

Cx43: connexin43, ACSF: artificial cerebrospinal fluid, HK-ACSF: incubated high (100 mM) K+ with Ca2+-free ACSF, GAP19: N-terminal transactivator of transcription GAP19 (selective Cx43 inhibitor), 10-[4′-(N,N-diethylamino)butyl]-2-chlorophenoxazine hydrochloride (protein kinase B inhibitor), non: no effect, increase: enhanced L-glutamate release or Cx43 expression, GAP19 (−): GAP19 insensitive, GAP19 (+): GAP19 sensitive, DEBC (−): DEBC insensitive, DEBC (+): DEBC sensitive.